

REMARKS

Claims 49-53, 54-57, and 99 are pending. Claims 58, 59, and 95-104 have been cancelled without prejudice to their prosecution in continuing applications.

Applicants thank the Examiner for renumbering claims 94-104.

Claims 49-59, 59, and 94-104 stand rejected under 35 U.S.C. §112, first paragraph, as lacking enablement. In particular, the Examiner argues that the specification only enables treatment of Alzheimer's disease. Applicants respectfully disagree but, solely to expedite prosecution of the application, have amended the claims to pertain only to Alzheimer's disease. These amendments overcome the § 112 rejection.

Claims 95-104 stand rejected under the judicially created doctrine of obviousness-type double patenting in view of claims 12 and 13 of U.S. Patent number 6,737,420. Applicant's cancellation of claims 95-104 overcomes this rejection.


Applicants respectfully submit that all requirements of patentability have been met. Allowance of the claims and passage of the case to issue are therefore respectfully solicited.

Response to April 12, 2005, Office Action
Serial No.: 09/816,876
Filed: March 23, 2001

Should the Examiner believe a discussion of this matter would be helpful, she is invited to telephone the undersigned at (312) 913-2136.

Respectfully submitted,

Dated

October 12, 2005 By: 

Steven J. Sarussi
Reg. No. 32,784

McDonnell Boehnen
Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001